Top-Rated StocksTop-RatedNASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $38.05 +0.88 (+2.37%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$38.03 -0.02 (-0.04%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harmony Biosciences Stock (NASDAQ:HRMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$37.17▼$38.2850-Day Range$31.57▼$38.0552-Week Range$26.47▼$41.61Volume500,603 shsAverage Volume528,117 shsMarket Capitalization$2.19 billionP/E Ratio12.27Dividend YieldN/APrice Target$51.00Consensus RatingBuy Company Overview Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Read More Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 94% of companies evaluated by MarketBeat, and ranked 73rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHarmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth27.98% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 12.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 12.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.80.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.44. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.66% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 5.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.66% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 5.17%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.46 News SentimentHarmony Biosciences has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Harmony Biosciences this week, compared to 8 articles on an average week.Search Interest11 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRMY Stock News HeadlinesHarmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy CongressAugust 26 at 8:05 AM | businesswire.comHarmony Biosciences to Participate in 2025 Cantor Global Healthcare ConferenceAugust 21, 2025 | businesswire.comThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the White House just greenlit a $30 trillion upgrade to our financial system. Big firms like JP Morgan and Goldman Sachs are already onboard. And our Wall Street insider expects this change to create more wealth in the next 5 years than major innovations like the computer. | Stansberry Research (Ad)Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid DrugAugust 20, 2025 | seekingalpha.comPiper Sandler Remains a Buy on Harmony Biosciences Holdings (HRMY)August 19, 2025 | theglobeandmail.comHarmony Biosciences Holdings (HRMY) Gets a Buy from Truist FinancialAugust 15, 2025 | theglobeandmail.comHarmony Biosciences Earnings Call Highlights Growth and InnovationAugust 15, 2025 | theglobeandmail.comMizuho Lifts Harmony Biosciences Target to $50, Citing Confidence in Fragile X TrialAugust 14, 2025 | msn.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $34.41 on January 1st, 2025. Since then, HRMY shares have increased by 10.6% and is now trading at $38.05. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings data on Tuesday, August, 5th. The company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by $0.10. The business's revenue for the quarter was up 16.0% on a year-over-year basis. Read the conference call transcript. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional investors include American Century Companies Inc. (2.61%), LSV Asset Management (2.59%), Marshall Wace LLP (2.10%) and Geode Capital Management LLC (1.83%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Jeffrey Dierks, Jeffrey M Dayno and Sandip Kapadia. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/05/2025Today8/27/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Harmony Biosciences$51.00 High Price Target$70.00 Low Price Target$33.00 Potential Upside/Downside+34.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$3.10 Trailing P/E Ratio12.27 Forward P/E Ratio15.66 P/E Growth0.44Net Income$145.49 million Net Margins23.44% Pretax Margin29.14% Return on Equity26.34% Return on Assets17.71% Debt Debt-to-Equity Ratio0.20 Current Ratio3.84 Quick Ratio3.80 Sales & Book Value Annual Sales$714.73 million Price / Sales3.06 Cash Flow$3.00 per share Price / Cash Flow12.70 Book Value$13.44 per share Price / Book2.83Miscellaneous Outstanding Shares57,530,000Free Float43,955,000Market Cap$2.19 billion OptionableOptionable Beta0.84 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:HRMY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.